ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

ClinicalTrials.gov ID: NCT05540860

Public ClinicalTrials.gov record NCT05540860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

Study identification

NCT ID
NCT05540860
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Enrollment
76 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sevasemten Dose 1 Drug
  • Sevasemten Dose 2 Drug
  • Sevasemten Dose 3 Drug
  • Sevasemten Dose 4 Drug
  • Sevasemten Dose 5 Drug

Drug

Eligibility (public fields only)

Age range
4 Years to 9 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 23, 2022
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026
Last update posted
Nov 11, 2025

2022 – 2027

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
Arkansas Children's Hospital Little Rock Arkansas 72202
UCLA Medical Center Los Angeles California 90095
UC Davis Medical Center Sacramento California 95817
Children's Hospital Colorado Aurora Colorado 80045
University of Florida Gainesville Florida 32610
Rare Disease Research Atlanta Georgia 30329
University of Iowa Iowa City Iowa 52242
University of Kansas Medical Center Kansas City Kansas 66160
Kennedy Krieger Institute Baltimore Maryland 21205
University of Massachusetts Memorial Medical Center Worcester Massachusetts 01605
Washington University School of Medicine St Louis Missouri 63110
Cincinnati Children's Hospital Cincinnati Ohio 45229
Nationwide Children's Hospital Columbus Ohio 43205
Cook Children's Medical Center Fort Worth Texas 76104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05540860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2025 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05540860 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →